Plain-English translation of NCT07089940 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called OMO-103 for people with advanced pancreatic cancer. OMO-103 works by targeting a protein called Myc, which helps cancer cells grow. Researchers want to understand how this medication affects tumors and whether it is safe and tolerable for patients.
Pancreatic cancer is a serious disease, especially when it has spread beyond the pancreas. This trial exists because doctors need new treatment options for patients with advanced pancreatic cancer, and this medication may offer a promising approach by working in a new way.
You likely qualify if…
You likely don't qualify if…
You would receive the medication through an IV infusion (into a vein) twice—on day 1 and day 8. You would have imaging scans (CT or MRI), tumor biopsies, and blood tests at various points during the study to monitor how the treatment is working and check for side effects. After the two doses, you would be followed up at 30 days and then for up to 1 year to see how you are doing.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States